Litcius/Paper detail

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

Solange Peters, Daniel S.W. Tan, David E. Gerber, James J. Urbanic, S.S. Ramalingam, Jin Yu, Ligang Xing, Achim Rittmeyer, T-E. Ciuleanu, J. Menezes, H.R. Kim, C.I. Rojas, Konstantinos Syrigos, Hirokatsu Hayashi, Anoop Haridass, Stéphanie Bordenave-Juchereau, Raheel Nathani, Geetha Pudussery, Ling Yang, Dirk De Ruysscher

2024Immuno-Oncology Technology18 citationsDOIOpen Access PDF

Topics & Concepts

DurvalumabNivolumabIpilimumabMedicineInternal medicineStage (stratigraphy)Phases of clinical researchOncologyCancerClinical trialImmunotherapyPaleontologyBiologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsRadiopharmaceutical Chemistry and Applications
65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC | Litcius